HPLC/MS findings in a fatality involving sustained-release verapamil

Human and Experimental Toxicology

Volumn 22, Issue 9, 2003, Pages 515-521

  Tracqui, Antoine ^a   Tournoud, C ^b   Kintz, P ^a   Villain, M ^a   Kummerlen, C ^b   Sauder, P ^b   Ludes, B ^a  

^a INSTITUT DE MÉDECINE LÉGALE   (France)

^b HÔPITAL CIVIL   (France)

Author keywords

HPLC MS; Poisoning; Sustained release; Toxicokinetics; Verapamil

Indexed keywords

ATROPINE; DOPAMINE; ISOPRENALINE; NORVERAPAMIL; VERAPAMIL;

ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD SAMPLING; BRADYCARDIA; CARDIOMYOPATHY; CASE REPORT; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG STRUCTURE; GLASGOW COMA SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; KIDNEY FAILURE; MALE; MASS SPECTROMETRY; METABOLIC ACIDOSIS; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RESUSCITATION; SUSTAINED RELEASE FORMULATION; TIME OF DEATH; URINALYSIS;

CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; FATAL OUTCOME; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; SUICIDE; VERAPAMIL;

EID: 0142011038     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327103ht389oa     Document Type: Article

References (56)

1. Litovitz TL, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Omslaer JC, Drab, A, Benson BE. 2000 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2001; 19: 337-95.
2. Pearigen PD, Benowitz NL. Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine. Drug Safe 1991; 6: 408-30.
3. Abernethy DR, Todd EL, Mitchell JR. Verapamil and norverapamil determination in human plasma by gasliquid chromatography using nitrogen-phosphorus detection: application to single-dose pharmacokinetic studies. Pharmacology 1984; 29: 264-68.
4. Todd GD, Bourne DW, McAllister RG Jr. Measurement of verapamil concentrations in plasma by gas chromatography and high pressure liquid chromatography. Therapeut Drug Monitor 1980; 2: 411-16.
5. Hynning PA, Anderson P, Bondesson U, Boreus LO. Liquid-chromatographic quantification compared with gas-chromatographic mass-spectrometric determination of verapamil and norverapamil in plasma. Clin Chem 1988; 34: 2502-503.
6. Maurer HH. Identification of antiarrhythmic drugs and their metabolites in urine. Arch Toxicol 1990; 64: 218-30.
7. Ceccato A, Chiap P, Hubert P, Toussaint B, Crommen J. Automated determination of verapamil and norverapamil in human plasma with on-line coupling of dialysis to high-performance liquid chromatography and fluorometric detection. J Chromatogr A 1996; 750: 351-60.
8. Sawicki W. A validated method for the determination of verapamil and norverapamil in human plasma. J Pharmaceut Biomed Anal 2001; 25: 689-95.
9. Koppel C, Wagemann A. Plasma level monitoring of D,L-verapamil and three of its metabolites by reversed-phase high-performance liquid chromatography. J Chromatogr 1991; 570: 229-34.
10. von Richter O, Eichelbaum M, Schonberger F, Hofmann U. Rapid and highly sensitive method for the determination of verapamil, [2H7]verapamil and metabolites in biological fluids by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 738: 137-47.
11. Siegner SW, Giovanoni RL, Erickson KA, Netland PA. Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. J Ocul Pharmacol Therapeut 1998; 14: 159-68.
12. Dilger K, Eckhardt K, Hofmann U, Kucher K, Mikus G, Eichelbaum M. Chronopharmacology of intravenous and oral modified release verapamil. Br J Clin Pharmacol 1999; 47:413-19.
13. Baselt RC. Verapamil. Disposition of toxic drugs and chemicals in man, fifth edition. Foster City: Chemical Toxicology Institute, 2000.
14. Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med 1993; 95: 431-38.
15. Horowitz BZ, Rhee KJ. Massive verapamil ingestion: a report of two cases and a review of the literature. Am J Emerg Med 1989; 7: 624-31.
16. Sauder P, Kopferschmitt J, Dahlet M, Tritsch L, Flesch F, Siard P, Mantz JM, Jaeger A. Les intoxications aiguës par le vérapamil. A propos de 6 cas. Revue de la littérature. J Toxicol Clin Exp 1990; 10: 261-70.
17. Watling SM, Crain JL, Edwards TD, Stiller RA. Verapamil overdose: case report and review of the literature. Ann Pharmacother 1992; 26: 1373-78.
18. Immonen P, Linkola A, Waris E. Three cases of severe verapamil poisoning. Int J Cordial 1981; 1: 101-105.
19. Ori Y, Korzets A, Caneti M, Weinstein T, Chagnac A, Salman H, Malachi T, Gafter U. Lymphocytic intracellular calcium in a patient with complicated verapamil overdose. Am J Med Sci 2000; 319: 63-67.
20. McMillan R. Management of acute severe verapamil intoxication. J Emerg Med 1988; 6: 193-96.
21. Brass BJ, Winchester-Penny S, Lipper BL. Massive verapamil overdose complicated by noncardiogenic pulmonary edema. Am J Emerg Med 1996; 14: 459-61.
22. Sami Karti S, Ulusoy H, Yandi M, Gunduz A, Kosucu M, Erol K, Ratip S. Non-cardiogenic pulmonary oedema in the course of verapamil intoxication. Emerg Med J 2002; 19: 458-59.
23. Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: a case report and review of literature. Am J Med Sci 1995; 310: 258-63.
24. Kline JA, Raymond RM, Schroeder JD, Watts JA. The diabetogenic effects of acute verapamil poisoning. Toxicol AppL Pharmacol 1997; 145: 357-62.
25. Eichelbaum M, Somogyi A, von Unruh GE, Dengler HJ. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol 1981; 19: 133-37.
26. Koike Y, Shimamura K, Shudo I, Saito H. Pharmacokinetics of verapamil in man. Res Commun Chem Pathol Pharmacol 1979; 24: 37-47.
27. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 1980; 46: 1047-58.
28. Sawicki W, Janicki S. Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation. Int J Pharmaceut 2002; 238: 181-89.
29. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 1986; 11: 425-49.
30. Hamann SR, Blouin RA, McAllister RG Jr. Clinical pharmacokinetics of verapamil. Clin Pharmacokinet 1984; 9: 26-41.
31. Frishman WH, Lazar EJ. Sustained-release verapamil formulations for treating hypertension. J Clin Pharmacol 1992; 32: 455-62.
32. Prisant LM. Verapamil revisited: a transition in novel drug delivery systems and outcomes. Heart Dis 2001; 3: 55-62.
33. Mayer U, Buhl N, Sachs H, Sigel H. Tödliche Vergiftung mit Verapamil in Retard-Form. Therapeutische Überlegungen. Dtsch Med Wochenschr 1985; 110: 1293-96.
34. Minocha A, Spyker DA. Acute overdose with sustained release drug formulations. Perspectives in treatment. Med Toxicol 1986; 1: 300-307.
35. Tom PA, Morrow CT, Kelen GD. Delayed hypotension after overdose of sustained release verapamil. J Emerg Med 1994; 12: 621-25.
36. Barrow PM, Houston PL, Wong DT. Overdose of sustained-release verapamil. Br J Anaesth 1994; 72: 361-65.
37. Buckley N, Dawson AH, Howarth D, Whyte IM. Slow-release verapamil poisoning. Use of polyethylene glycol whole-bowel lavage and high-dose calcium. Med J Austr 1993; 158: 202-204.
38. Sporer KA, Manning JJ. Massive ingestion of sustained-release verapamil with a concretion and bowel infarction. Ann Emerg Med 1993; 22: 603-605.
39. Spiller HA, Meyers A, Ziemba T, Riley M. Delayed onset of cardiac arrhythmias from sustained-release verapamil. Ann Emerg Med 1991; 20: 201-203.
40. McDonald D, Alguire PC. Case report: fatal overdose with sustained-release verapamil. Am J Med Sci 1992; 303: 115-17.
41. Krick SE, Gums JG, Grauer K, Cooper GR. Severe verapamil (sustained-release) overdose. DICP 1990; 24: 705-706.
42. Rankin RJ, Edwards IR. Overdose of sustained release verapamil. N Z Med J 1990; 103: 165.
43. Stack PE, Thomas E. Pharmacobezoar: an evolving new entity. Digest Dis 1995; 13: 356-64.
44. Taylor JR, Streetman DS, Castle SS. Medication bezoars: a literature review and report of a case. Ann Pharmacother 1998; 32: 940-46.
45. Buckley NA, Dawson AH, Reith DA. Controlled release drugs in overdose. Clinical considerations. Drug Safe 1995; 12: 73-84.
46. Bernstein G, Jehle D, Bernaski E, Braen GR. Failure of gastric emptying and charcoal administration in fatal sustained-release theophylline overdose: pharmacobezoar formation. Ann Emerg Med 1992; 21: 1388-90.
47. Bogacz K, Caldron P. Enteric-coated aspirin bezoar: elevation of serum salicylate level by barium study. Case report and review of medical management. Am J Med 1987; 83: 783-86.
48. Niezabitowski LM, Nguyen BN, Gums JG. Extended-release nifedipine bezoar identified one year after discontinuation. Ann Pharmacother 2000; 34: 862-64.
49. Shepherd MF. Bezoar formed by fragments of extended-release nifedipine tablets. Clin Pharm 1993; 12: 849-52.
50. Stack PE, Patel NR, Young MF, Ferslew KE, Thomas E. Pharmacobezoars-the irony of the antidote: first case report of nifedipine XL bezoar. J Clin Gastroenterol 1994; 19: 264-65.
51. Toffoli G, Robieux I, Fantin D, Gigante M, Frustaci S, Nicolosi GL, De Cicco M, Boiocchi M. Non-linear pharmacokinetics of high-dose intravenous verapamil. Br J Clin Pharmacol 1997; 44: 255-60.
52. Kivisto KT, Neuvonen PJ, Tarssanen L. Pharmacokinetics of verapamil in overdose. Hum Exp Toxicol 1997; 16: 35-37.
53. Zachariah PK, Moyer TP, Theobald HM, Frantz RP, Kurtz SB, McCarthy JT, Smith RL. The pharmacokinetics of racemic verapamil in patients with impaired renal function. J Clin Pharmacol 1991; 31: 45-53.
54. Hanyok JJ, Chow MS, Kluger J, Izard MW. An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients. J Clin Pharmacol 1988; 28: 831-36.
55. Mooy J, Schols M, v'Baak M, v'Hooff M, Muytjens A, Rahn KH. Pharmacokinetics of verapamil in patients with renal failure. Eur J Clin Pharmacol 1985; 28: 405-10.
56. Pritza DR, Bierman MH, Hammeke MD. Acute toxic effects of sustained-release verapamil in chronic renal failure. Arch Intern Med 1991; 151: 2081-84.